Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

9431 ARTÍCULOS , VIENDO DEL 6781 AL 6795

A meta-analysis of the relationship of the Parkin p.Val380Leu polymorphism to Parkinson's disease

Zhang Y, Wang ZZ, Sun HM.

Am J Med Genet B Neuropsychiatr Genet. 2013 Apr;162B(3):235-44. doi: 10.1002/ajmg.b.32138. Epub 2013 Feb 21.

Instruments for holistic assessment of Parkinson's disease

Martinez-Martin P.

J Neural Transm (Vienna). 2013 Apr;120(4):559-64. doi: 10.1007/s00702-013-1005-1. Epub 2013 Mar 10.

Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes

Bajaj N, Hauser RA, Grachev ID.

J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1288-95. doi: 10.1136/jnnp-2012-304436. Epub 2013 Mar 13.

A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease

Corcos DM, Robichaud JA, David FJ, Leurgans SE, Vaillancourt DE, Poon C, Rafferty MR, Kohrt WM, Comella CL.

Mov Disord. 2013 Aug;28(9):1230-40. doi: 10.1002/mds.25380. Epub 2013 Mar 27.

Mesenchymal stem cells and neuroregeneration in Parkinson's disease

Glavaski-Joksimovic A, Bohn MC.

Exp Neurol. 2013 Sep;247:25-38. doi: 10.1016/j.expneurol.2013.03.016. Epub 2013 Mar 28.

Pharmacologic treatment of anxiety disorders in Parkinson disease

Pontone GM, Williams JR, Anderson KE, Chase G, Goldstein SR, Grill S, Hirsch ES, Lehmann S, Little JT, Margolis RL, Palanci J, Rabins PV, Weiss HD, Marsh L.

Am J Geriatr Psychiatry. 2013 Jun;21(6):520-8. doi: 10.1016/j.jagp.2012.10.023. Epub 2013 Mar 29.

[Elaboration of the SPM template for the standardization of SPECT images with 123I-Ioflupane]

García-Gómez FJ, García-Solís D, Luis-Simón FJ, Marín-Oyaga VA, Carrillo F, Mir P, Vázquez-Albertino RJ.

Rev Esp Med Nucl Imagen Mol. 2013 Nov-Dec;32(6):350-6. doi: 10.1016/j.remn.2013.02.009. Epub 2013 Apr 6.

Contribution of β-phenethylamine, a component of chocolate and wine, to dopaminergic neurodegeneration: implications for the pathogenesis of Parkinson's disease

Borah A, Paul R, Mazumder MK, Bhattacharjee N.

Neurosci Bull. 2013 Oct;29(5):655-60. doi: 10.1007/s12264-013-1330-2. Epub 2013 Apr 10.

A neuroprosthesis for tremor management through the control of muscle co-contraction

Gallego JÁ, Rocon E, Belda-Lois JM, Pons JL.

J Neuroeng Rehabil. 2013 Apr 15;10:36. doi: 10.1186/1743-0003-10-36.

The role of the cerebellum in the pathophysiology of Parkinson's disease

Lewis MM, Galley S, Johnson S, Stevenson J, Huang X, McKeown MJ.

Can J Neurol Sci. 2013 May;40(3):299-306. doi: 10.1017/s0317167100014232.

The heterogeneity of cognitive symptoms in Parkinson's disease: a meta-analysis

Tremblay C, Achim AM, Macoir J, Monetta L.

J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1265-72. doi: 10.1136/jnnp-2013-305021. Epub 2013 Apr 20.

Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale

Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG.

Eur J Neurol. 2015 Jan;22(1):37-43. doi: 10.1111/ene.12165. Epub 2013 Apr 22.

Head injury and risk of Parkinson disease: a systematic review and meta-analysis

Jafari S, Etminan M, Aminzadeh F, Samii A.

Mov Disord. 2013 Aug;28(9):1222-9. doi: 10.1002/mds.25458. Epub 2013 Apr 22.

Effect of expectancy and personality on cortical excitability in Parkinson's disease

Lou JS, Dimitrova DM, Hammerschlag R, Nutt J, Hunt EA, Eaton RW, Johnson SC, Davis MD, Arnold GC, Andrea SB, Oken BS.

Mov Disord. 2013 Aug;28(9):1257-62. doi: 10.1002/mds.25471. Epub 2013 Apr 29.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias